Chidamide, a histone deacetylase (HDAC) inhibitor, can significantly downregulate HMGB1 expression and confers therapeutic effect on AML by inducing cell differentiation, apoptosis, and inhibiting cell proliferation. The gene discussed is HMGB1; the disease is acute myeloid leukemia.